Crisantaspase (recombinant Erwinia asparaginase)
Enrylaze is a replacement asparaginase for children and adults with acute lymphoblastic leukaemia or lymphoblastic lymphoma whose bodies have reacted against, or quietly neutralised, the usual E. coli asparaginase. It keeps the asparagine-starving part of their chemotherapy going.
Overview
Crisantaspase (Enrylaze) is authorised in the EU since 15 September 2023 (CHMP opinion 20 July 2023; marketing authorisation holder Jazz Pharmaceuticals Ireland Limited) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukaemia and lymphoblastic lymphoma in adults and children from one month of age who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. It is under additional monitoring in the EU. The class record `asparaginase` covers pegaspargase, calaspargase pegol and the native Erwinia enzyme; this record is the recombinant Erwinia product.
Asparaginase enzyme that depletes circulating asparagine, on which lymphoblasts depend; the recombinant Erwinia enzyme is given to patients who have reacted to or silently inactivated E. coli-derived asparaginase (indication wording, EMA).
1.Crisantaspase (recombinant Erwinia asparaginase) binds its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| EU | 2023 | ALL and lymphoblastic lymphoma, in a multi-agent regimen, after hypersensitivity or silent inactivation to E. coli-derived asparaginase (adults and children from 1 month) · Authorised 15 Sep 2023; Jazz Pharmaceuticals Ireland |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Crisantaspase" OR ABSTRACT:"Crisantaspase" OR TITLE:"recombinant Erwinia asparaginase" OR ABSTRACT:"recombinant Erwinia asparaginase" OR TITLE:"Enrylaze" OR ABSTRACT:"Enrylaze" OR TITLE:"crisantaspase" OR ABSTRACT:"crisantaspase" OR TITLE:"recombinant Erwinia chrysanthemi asparaginase" OR ABSTRACT:"recombinant Erwinia chrysanthemi asparaginase" OR TITLE:"JZP-458" OR ABSTRACT:"JZP-458") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Crisantaspase (recombinant Erwinia asparaginase), not a curated reading list.
Similar pages
not linked directly; found by shared links- CompanyPhaxiam Therapeutics (formerly ERYtech Pharma)
Shares Eryaspase, Acute lymphoblastic leukaemia.
- TrialAALL1231
Shares Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase), High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL), Acute lymphoblastic leukaemia.
- TrialAALL0232
Shares Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase), High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL), Acute lymphoblastic leukaemia.
- TreatmentThioguanine
Shares Standard-risk B-cell acute lymphoblastic leukaemia in children, High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL).
- TreatmentMercaptopurine
Shares Standard-risk B-cell acute lymphoblastic leukaemia in children, High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL), Acute lymphoblastic leukaemia.
- TreatmentAminopterin
Shares Standard-risk B-cell acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia.
- Key paperAALL1231: bortezomib in newly diagnosed T-cell acute lymphoblastic leukaemia and lymphoma, with cranial radiotherapy removed
Shares High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL), Acute lymphoblastic leukaemia.
- IdeaMake paediatric combination studies part of every relevant adult cancer drug approval
Shares Standard-risk B-cell acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia.